Cybin Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

222.66M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	-	-	-
Mar 31, 2024	-	-	-
Mar 31, 2023	-	-	-
Mar 31, 2022	-	-	-
Mar 31, 2021	686.88K	-	-
Mar 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Keros Therapeutics	244.06M
Editas Medicine	40.52M
C4 Therapeutics	35.95M
Alector	21.05M
Sol-Gel Technologies	19.39M
OmniAb	18.67M
Camp4 Therapeutics	3.50M

Revenue Rankings

HELP News

19 days ago - Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - GlobeNewsWire
24 days ago - Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript - Seeking Alpha
25 days ago - Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga
26 days ago - Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - GlobeNewsWire
4 weeks ago - HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
5 weeks ago - Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - GlobeNewsWire
6 weeks ago - Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - GlobeNewsWire
6 weeks ago - HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - GlobeNewsWire

More News